On Monday morning 07/22/2024 the Sanofi S.A. (spons. ADRs) share started trading at the price of $50.97.
Compared to the closing price on Friday 07/19/2024 on BTT of $50.64, this is a gain of 0.65%.
Sanofi Stock Snapshot
51.01
Bid
300.00
Bid Size
51.04
Ask
88.00
Ask Size
7/22/2024
Date
12:02 PM
Time
36,773.00
Volume
50.64
Prev. Close
50.97
Open
2.51 B
Number of Shares
50.87
Day Low
51.28
Day High
51.03
42.63
52 Week Low
55.72
52 Week High
51.03
1.48
Dividend in USD
2.97
Dividend Yield
21.33
P/E Ratio
100.00
Free Float in %
2.33
EPS in USD
32.68
Book Value per Share in USD
4.41
Cash Flow per Share in USD
Sanofi News More News
Historical Prices for Sanofi
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:
0%
0
Sanofi Analyst Data
Total Analysts: 2
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price
*Price Target
Lowest: 55.00
Median: 57.50
Highest: 60.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
Sanofi Analyst Opinions
- All
- Buy
- Hold
- Sell
| Date | Analyst | Rating | Price | |||
|---|---|---|---|---|---|---|
| 01/23/24 | Morgan Stanley | Maintained Hold | $55 | |||
| 03/27/23 | Argus Research Company | Maintained Buy | $60 | |||
| 08/12/22 | Deutsche Bank | Upgraded to Hold |
Sanofi Estimates* in USD
| 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|
| Revenue | 51,055 | 54,486 | 57,873 | 61,156 | 63,644 |
| Dividend | 2.07 | 2.19 | 2.40 | 2.57 | 2.56 |
| Dividend Yield (in %) | 4.09 % | 4.33 % | 4.74 % | 5.07 % | 5.06 % |
| EPS | 4.11 | 4.70 | 5.15 | 5.55 | 6.08 |
| P/E Ratio | 12.31 | 10.78 | 9.83 | 9.12 | 8.32 |
| EBIT | 13,297 | 14,937 | 16,465 | 17,516 | 18,755 |
| EBITDA | 14,847 | 16,698 | 17,954 | 19,102 | 20,357 |
| Net Profit | 10,251 | 11,638 | 12,712 | 13,766 | 14,848 |
| Net Profit Adjusted | 10,251 | 11,638 | 12,682 | 13,689 | 14,848 |
| Pre-Tax Profit | 12,189 | 13,911 | 15,434 | 16,705 | 18,091 |
| Net Profit (Adjusted) | 9,148 | 11,270 | 12,067 | 15,146 | 15,583 |
| EPS (Non-GAAP) ex. SOE | - | - | - | - | - |
| EPS (GAAP) | 3.06 | 3.69 | 4.04 | 4.32 | 5.12 |
| Gross Income | 36,030 | 39,053 | 41,578 | 44,356 | 46,923 |
| Cash Flow from Investing | -6,160 | -6,685 | -7,519 | -6,546 | -7,249 |
| Cash Flow from Operations | 10,895 | 12,931 | 13,900 | 15,123 | 16,934 |
| Cash Flow from Financing | -6,160 | -6,685 | -7,519 | -6,546 | -7,249 |
| Cash Flow per Share | 4.28 | 5.00 | 5.47 | 6.04 | 6.74 |
| Free Cash Flow | 7,730 | 9,956 | 10,764 | 11,452 | 13,423 |
| Free Cash Flow per Share | 3.18 | 3.91 | 4.21 | 4.75 | 5.20 |
| Book Value per Share | 33.41 | 35.11 | 37.02 | 38.84 | 42.55 |
| Net Debt | 4,923 | 835 | -3,375 | -2,941 | -7,540 |
| Research & Development Exp. | 8,144 | 8,328 | 8,564 | 8,814 | 9,056 |
| Capital Expenditure | 2,714 | 2,881 | 2,967 | 3,214 | 3,148 |
| Selling, General & Admin. Exp. | 11,827 | 12,051 | 12,310 | 12,722 | 13,061 |
| Shareholder’s Equity | 82,764 | 86,804 | 90,807 | 95,942 | 104,164 |
| Total Assets | 139,613 | 143,842 | 145,644 | 151,573 | 160,317 |
|
Previous Quarter ending 06/30/24 |
Current Quarter ending 09/30/24 |
Next Quarter ending 12/31/24 |
Current Year ending 12/31/24 |
Next Year ending 12/31/25 |
|
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | 11 | 7 | 7 | 22 | 22 |
| Average Estimate | 0.892 USD | 1.392 USD | 0.896 USD | 4.111 USD | 4.698 USD |
| Year Ago | - | - | - | 2.332 USD | - |
| Publish Date | 7/25/2024 | 10/25/2024 | 1/31/2025 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | 12 | 7 | 7 | 20 | 20 |
| Average Estimate | 11,638 USD | 14,505 USD | 13,550 USD | 51,055 USD | 54,486 USD |
| Year Ago | - | - | - | 46,564 USD | - |
| Publish Date | 7/25/2024 | 10/25/2024 | 1/31/2025 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Income Statements in Mio. USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Sales | 46,563.65 | 45,188.74 | 44,632.78 | 41,085.82 | 40,433.98 | 40,657.72 | 39,539.75 |
| Change of sales in % | 3.04 | 1.25 | 8.63 | 1.61 | -0.55 | 2.83 | 5.69 |
| Gross profit on sales | 28,647.40 | 28,525.54 | 28,147.69 | 25,177.48 | 24,462.30 | 24,468.01 | 24,206.60 |
| Gross profit on sales change in % | 0.43 | 1.34 | 11.80 | 2.92 | -0.02 | 1.08 | 2.65 |
| Operating income | 9,927.88 | 10,542.32 | 10,245.41 | 8,291.03 | 6,802.79 | 5,994.31 | 6,784.53 |
| Operating income change in % | -5.83 | 2.90 | 23.57 | 21.88 | 13.49 | -11.65 | -8.88 |
| Income before tax | 7,733.22 | 10,953.25 | 9,217.09 | 15,736.21 | 3,158.52 | 5,196.80 | 6,237.48 |
| Income before tax change in % | -29.40 | 18.84 | -41.43 | 398.21 | -39.22 | -16.68 | -0.69 |
| Income after tax | 5,838.02 | 8,797.71 | 7,355.47 | 14,037.65 | 3,253.66 | 5,095.34 | 4,276.00 |
| Income after tax change in % | -33.64 | 19.61 | -47.60 | 331.44 | -36.14 | 19.16 | -17.91 |
Balance Sheet in Mio. USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Total liabilities | 57,564.42 | 55,038.08 | 58,237.15 | 62,868.45 | 60,197.43 | 59,870.19 | 49,914.85 |
| Long-term liabilities per share | 12.32 | 11.76 | 13.58 | 15.72 | 14.88 | 16.06 | 12.50 |
| Equity | 82,134.04 | 80,205.97 | 78,502.05 | 77,263.51 | 66,348.73 | 67,485.86 | 69,956.21 |
| Equity change in % | 2.47 | 2.19 | 1.32 | 16.52 | -1.71 | -3.51 | 14.91 |
| Balance sheet total | 139,698.46 | 135,244.05 | 136,739.20 | 140,131.96 | 126,546.16 | 127,356.06 | 119,871.06 |
| Balance sheet total change in % | 3.29 | -1.09 | -2.42 | 10.74 | -0.64 | 6.24 | 8.58 |
Key Data in USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Sales per share | 18.53 | 17.98 | 17.74 | 16.30 | 16.08 | 16.20 | 15.61 |
| P/E ratio (year end quote, basic EPS) | 21.33 | 13.78 | 17.06 | 8.68 | 38.57 | 21.25 | 25.25 |
| P/E ratio (year end quote, diluted EPS) | 21.40 | 13.84 | 17.14 | 8.72 | 38.79 | 21.39 | 25.50 |
| P/E ratio (year end quote) | 21.33 | 13.78 | 17.06 | 8.68 | 38.57 | 21.25 | 25.25 |
| Dividend yield in % | 2.97 | 2.84 | 2.52 | 2.81 | 2.34 | 2.69 | 2.80 |
| Equity ratio in % | 58.55 | 59.01 | 57.12 | 55.01 | 52.28 | 52.85 | 58.19 |
| Debt ratio in % | 41.21 | 40.70 | 42.59 | 44.86 | 47.57 | 47.01 | 41.64 |
Sanofi Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2023 | Sanofi S.A. (spons. ADRs) | 1.48 | 2.97 | USD |
| 2022 | Sanofi S.A. (spons. ADRs) | 1.38 | 2.84 | USD |
| 2021 | Sanofi S.A. (spons. ADRs) | 1.26 | 2.52 | USD |
| 2020 | Sanofi S.A. (spons. ADRs) | 1.37 | 2.81 | USD |
| 2019 | Sanofi S.A. (spons. ADRs) | 1.17 | 2.34 | USD |
| 2018 | Sanofi S.A. (spons. ADRs) | 1.17 | 2.69 | USD |
| 2017 | Sanofi S.A. (spons. ADRs) | 1.20 | 2.80 | USD |
| 2016 | Sanofi S.A. (spons. ADRs) | 1.10 | 2.72 | USD |
| 2015 | Sanofi S.A. (spons. ADRs) | 1.12 | 2.64 | USD |
| 2014 | Sanofi S.A. (spons. ADRs) | 1.09 | 2.38 | USD |
| 2013 | Sanofi S.A. (spons. ADRs) | 1.32 | 2.46 | USD |
| 2012 | Sanofi S.A. (spons. ADRs) | 1.25 | 2.65 | USD |
| 2011 | Sanofi S.A. (spons. ADRs) | 1.43 | 3.92 | USD |
| 2010 | Sanofi S.A. (spons. ADRs) | 1.32 | 4.10 | USD |
| 2009 | Sanofi S.A. (spons. ADRs) | 1.10 | 2.81 | USD |
| 2008 | Sanofi S.A. (spons. ADRs) | 2.07 | - | EUR |
| 2007 | Sanofi S.A. (spons. ADRs) | 1.04 | - | EUR |
| 2006 | Sanofi S.A. (spons. ADRs) | 0.76 | - | EUR |
| 2005 | Sanofi S.A. (spons. ADRs) | 0.60 | - | EUR |
| 2004 | Sanofi S.A. (spons. ADRs) | 0.51 | - | EUR |
| 2003 | Sanofi S.A. (spons. ADRs) | 0.42 | - | EUR |
| 2002 | Sanofi S.A. (spons. ADRs) | 0.33 | - | EUR |
| 2001 | Sanofi S.A. (spons. ADRs) | 0.22 | - | EUR |
*Yield of the Respective Date
Sanofi S.A. (spons. ADRs) Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Earnings Report | 0.892 USD | Q2 2024 Earnings Release | 07/25/2024 |
| Earnings Report | 1.392 USD | Q3 2024 Earnings Release | 10/25/2024 |
| Earnings Report | 0.896 USD | Q4 2024 Earnings Release | 01/31/2025 |
| Earnings Report | 1.034 USD | Q1 2025 Earnings Release | 04/24/2025 |
| Earnings Report | 0.930 USD | Q2 2025 Earnings Release | 07/24/2025 |
| Earnings Report | 1.528 USD | Q3 2025 Earnings Release | 10/24/2025 |
Sanofi S.A. (spons. ADRs) Past Events
| Event | Actual EPS | Info | Date |
|---|---|---|---|
| Annual General Meeting | - | Annual General Meeting | 04/30/2024 |
| Press Conference | - | - | 04/25/2024 |
| Earnings Report | - | Q1 2024 Earnings Release | 04/25/2024 |
| Press Conference | - | - | 02/01/2024 |
Sanofi Profile
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Sanofi Shareholder
| Owner | in % |
|---|---|
| Freefloat | 100.00 |
| Dodge & Cox | 3.09 |
| Dodge & Cox | 3.08 |
| Dodge & Cox Stock Fund | 2.30 |
| Fisher Asset Management LLC | 0.55 |
| Boston Partners Global Investors, Inc. | 0.52 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.